Karyopharm Therapeutics (KPTI) Exchange Rate Effect (2015 - 2025)
Karyopharm Therapeutics' (KPTI) quarterly Exchange Rate Effect came in at $5000.0 in Q4 2025, up 125.0% YoY from $2222.2 in Q4 2024, and up 150.0% on a QoQ basis from $2000.0 in Q3 2025.
Karyopharm Therapeutics (KPTI) Exchange Rate Effect (2015 - 2025) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 11 years of Exchange Rate Effect data on file, last reported at $5000.0 in Q4 2025.
- Quarterly Exchange Rate Effect rose 125.0% year-over-year to $5000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $20000.0 (up 281.82% YoY) and the FY2025 annual result came in at $20000.0, up 281.82% from the prior year.
- Exchange Rate Effect grew to $5000.0 in Q4 2025, from $2000.0 in the prior quarter.
- In the past five years, Exchange Rate Effect ranged from a high of $242000.0 in Q3 2021 to a low of -$454000.0 in Q2 2022.
- A 5-year average of -$28050.0 and a median of -$18000.0 in 2024 frame the typical range for Exchange Rate Effect.
- Annual changes were most pronounced in 2021 — Exchange Rate Effect surged 1323.53% — and 2022, when it plunged 609.38%.
- Tracing KPTI's Exchange Rate Effect over 5 years: stood at -$135000.0 in 2021, then surged by 193.33% to $126000.0 in 2022, then decreased by 29.37% to $89000.0 in 2023, then sank by 122.47% to -$20000.0 in 2024, then soared by 125.0% to $5000.0 in 2025.
- The last three Exchange Rate Effect figures came in at $5000.0 (Q4 2025), $2000.0 (Q3 2025), and $8000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -2.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.84 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -2.45 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -287,000.00 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.63 Mn |
| 10 | Karyopharm Therapeutics | 53.25 Mn | 53.25 Mn | 32.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5,000.00 |
| Dec 31, 2025 | 5,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 8,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Dec 31, 2024 | -20,000.00 |
| Dec 31, 2024 | -20,000.00 |
| Sep 30, 2024 | 36,000.00 |
| Sep 30, 2024 | 36,000.00 |
| Jun 30, 2024 | -11,000.00 |
| Jun 30, 2024 | -11,000.00 |
| Mar 31, 2024 | -16,000.00 |
| Mar 31, 2024 | -16,000.00 |
| Dec 31, 2023 | 89,000.00 |
| Dec 31, 2023 | 89,000.00 |
| Sep 30, 2023 | -52,000.00 |
| Sep 30, 2023 | -52,000.00 |